48 results about "Rhabdomyosarcoma" patented technology

Method of treating persons having carcinoma, sarcoma or hematopoietic cancer by administering (i) a compound of the formula (I)and (ii) an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor and pharmaceutical compositions for use in said method. A method for treating gastric cancer, colon cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma and leukemia by administering a compound of the formula (I).

A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.

The invention discloses a fluorescent probe and a kit for carrying out differential diagnosis on leukemia and bone marrow metastasis of rhabdomyosarcoma and neuroblastoma by using flow cytometry. The fluorescent probe comprises four fluorescence labeled antibodies; the four fluorescence labeled antibodies comprise a GD2 antibody, a CD90 antibody, a CD45 antibody and a CD56 antibody which take fluorescence labels; the different antibodies take the different fluorescence labels. The kit comprises a probe solution, a hemolytic agent, a phosphate buffer and a positive standard product. The fluorescent probe can be respectively and specifically combined with cells of the rhabdomyosarcoma and the neuroblastoma in bone marrow and original cells of acute leukemia; three tumor cells which are common in the child bone marrow, such as the bone marrow metastasis of the rhabdomyosarcoma and the neuroblastoma and the leukemia cells, can be rapidly and accurately identified by the flow cytometry, so as to guide clinical treatment; the application prospect is very good.

The invention provides a preparation method of angelica sinensis and flowers carthami dieda (Chinese character) pills. The pills are prepared from the following crude drugs: 175g of angelica sinensis, 175g of radices sileris, 175g of flowers carthami, 175g of processed rhizoma arisaematis, 120g of radix angelicae, 50g of pseudo-ginseng and 100g of cucumber seeds in a supercritical extraction manner. Thus, the content is greatly improved, and the dose is reduced. The invention also provides application of the angelica sinensis and flowers carthami dieda pills in preparation of a drug for inhibiting rhabdomyosarcoma A-204 cell proliferation.

The invention relates to the field of medicines, and particularly relates to intratumoral injection for treating rhabdomyosarcoma. The intratumoral injection is prepared from the following componentsin parts by weight: 11-21 parts of tanshinol, 2-5 parts of 2,5-dimethoxy-4-Iodophenyl dimethylmethane-2-amine hydrochloride, and a pharmaceutically acceptable medicinal auxiliary material which is preferably prepared from mannitol, sodium acetate and injection water, wherein the tanshinol has a certain effect for resisting rhabdomyosarcoma; and no anti-tumor effect for a rhabdomyosarcoma cell lineand animal model is found in 2,5-dimethoxy-4-Iodophenyl dimethylmethane-2-amine hydrochloride, but cell and animal experiments indicate that 2,5-dimethoxy-4-Iodophenyl dimethylmethane-2-amine hydrochloride has a remarkable synergistic effect for the rhabdomyosarcoma resistance of tanshinol. The intratumoral injection has excellent safety in intratumoral injection.

The present invention provides inhibitors or antagonists of PAX3-FKHR gene or its encoded protein, activator or accelerator of RhoA / MKL1 / SRF signaling pathway and ACTA1 gene or its encoded protein in screening and preparing striated muscle Use in a therapeutic agent for sarcoma, preferably alveolar rhabdomyosarcoma. The present invention discloses a mechanism of the occurrence and development of alveolar rhabdomyosarcoma and the potential clinical application value of the mechanism in rhabdomyosarcoma, preferably in the treatment and prognosis of alveolar rhabdomyosarcoma.

The invention discloses an application of osteopetrosis-related transmembrane protein in a medicine for treatment or prevention of EV71 infection. The application comprises the following steps: firstly, expressing Ostml protein by an insect baculovirus expression system in an insect cell (SF9); purifying the Ostml protein by a nickel column affinity chromatography method; and finally, validating the antiviral effect of the Ostml protein in EV71-infected malignant rhabdomyosarcoma cells (RD cell). An experiment result proves that the purified Ostml protein is capable of inhibiting EV71 virus replication in mRNA level and protein level at certain concentration. The anti-EV71 virus effect of the osteopetrosis-related transmembrane protein (Ostml) is evaluated from protein purification and nucleus molecular level; a foundation is laid for further development and application. The protein is capable of directly inhibiting EV71 virus replication at proper concentration, is obvious in effect and free of a side effect on the cell, and simple and convenient to use. The medicine has the prospect that the medicine can be developed into an anti-EV71 virus effective medicine for clinical application.